MedTrace Logo

To Determine the Effect of Nebivolol on Office Blood Pressure of Blacks Residing in Nigeria

NCT03598673 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2021-08-19

No results posted yet for this study

Summary

Although Nebivolol, a highly selective beta-1 agent has been shown to be effective in reducing blood pressure in Blacks, this was in African Americans with no study in Blacks residing in sub Saharan Africa. We therefore decided to study the effectiveness and safety of Nebivolol in Black patients with stage 1 hypertension (systolic BP of 140-149 and/or diastolic BP of 90-99 mmHg) presenting to five primary care centres in Nigeria.

Conditions

Interventions

DRUG

The Efficacy and Tolerability of Nebivolol in Nigerians

To determine the effect of Nevibolol on office blood pressure of Blacks residing in Nigeria

Sponsors & Collaborators

  • Micronova Pharmaceuticals Ind Ltd

    collaborator UNKNOWN

  • University of Abuja

    lead OTHER

Eligibility

Min Age
30 Years
Max Age
59 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-02-27
Primary Completion
2018-12-27
Completion
2019-04-27

Countries

  • Nigeria

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03598673 on ClinicalTrials.gov